These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt||2005-004313-15||A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease||2006-12-10||not-yet-due|
|Listed as ongoing, but also has a completion date||2007-001857-24||A Phase IIa, open-label, dose-titration, multicenter study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection||2008-12-03||bad-data|
|Not reported Terminated||2009-012988-34||A multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of NI-0401 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D)||2009-10-26||due-trials|
|Not reported Terminated||2011-001326-26||PIANO. Primary Biliary Cirrhosis: Investigating A New Treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody. An open label single arm study to investigate the safety and effica...||2012-10-10||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-003632-23||A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-...||2019-01-04||bad-data|
|Listed as ongoing, but also has a completion date||2012-005753-23||A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody||2017-12-21||bad-data|
|Listed as ongoing, but also has a completion date||2016-004223-23||A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) mo...||2020-05-19||bad-data|
|Reported results||2016-005017-45||A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101,...||2018-05-17||due-trials|
|Ongoing||2017-003114-10||An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, a...||not-yet-due|